SE539575C2 - Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis - Google Patents
Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis Download PDFInfo
- Publication number
- SE539575C2 SE539575C2 SE1551050A SE1551050A SE539575C2 SE 539575 C2 SE539575 C2 SE 539575C2 SE 1551050 A SE1551050 A SE 1551050A SE 1551050 A SE1551050 A SE 1551050A SE 539575 C2 SE539575 C2 SE 539575C2
- Authority
- SE
- Sweden
- Prior art keywords
- dextran sulfate
- pharmaceutically acceptable
- acceptable salt
- fibrosis
- use according
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims abstract description 123
- 230000002401 inhibitory effect Effects 0.000 title claims description 18
- 230000009787 cardiac fibrosis Effects 0.000 title claims description 10
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 66
- 230000004761 fibrosis Effects 0.000 claims abstract description 66
- 238000007910 systemic administration Methods 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims description 58
- 208000010125 myocardial infarction Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 210000002216 heart Anatomy 0.000 claims description 13
- 206010061216 Infarction Diseases 0.000 claims description 11
- 230000007574 infarction Effects 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 3
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000002939 deleterious effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- 229960002086 dextran Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002303 citric acid monohydrate Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000000266 injurious effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- -1 0.9 % NaCl saline Chemical compound 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
| DK16830923.5T DK3328395T3 (da) | 2015-07-30 | 2016-07-15 | Ny brug af dextransulfat |
| CN202210555037.5A CN114712385A (zh) | 2015-07-30 | 2016-07-15 | 硫酸葡聚糖的新用途 |
| BR112018001942A BR112018001942A2 (pt) | 2015-07-30 | 2016-07-15 | ?novo uso de sulfato de dextrano? |
| ES16830923T ES2882115T3 (es) | 2015-07-30 | 2016-07-15 | Nuevo uso de sulfato de dextrano |
| HK18106000.5A HK1246640A1 (zh) | 2015-07-30 | 2016-07-15 | 硫酸葡聚糖的新用途 |
| US15/748,519 US10478451B2 (en) | 2015-07-30 | 2016-07-15 | Use of dextran sulfate |
| JP2018503496A JP6837679B2 (ja) | 2015-07-30 | 2016-07-15 | 硫酸デキストランの新しい使用 |
| EA201890212A EA034313B1 (ru) | 2015-07-30 | 2016-07-15 | Применение сульфата декстрана |
| EP16830923.5A EP3328395B1 (en) | 2015-07-30 | 2016-07-15 | New use of dextran sulfate |
| PCT/SE2016/050720 WO2017018922A1 (en) | 2015-07-30 | 2016-07-15 | New use of dextran sulfate |
| CN201680044788.3A CN107921055A (zh) | 2015-07-30 | 2016-07-15 | 硫酸葡聚糖的新用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1551050A1 SE1551050A1 (en) | 2017-01-31 |
| SE539575C2 true SE539575C2 (en) | 2017-10-17 |
Family
ID=57884849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10478451B2 (enExample) |
| EP (1) | EP3328395B1 (enExample) |
| JP (1) | JP6837679B2 (enExample) |
| CN (2) | CN114712385A (enExample) |
| BR (1) | BR112018001942A2 (enExample) |
| DK (1) | DK3328395T3 (enExample) |
| EA (1) | EA034313B1 (enExample) |
| ES (1) | ES2882115T3 (enExample) |
| HK (1) | HK1246640A1 (enExample) |
| SE (1) | SE539575C2 (enExample) |
| WO (1) | WO2017018922A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212708A1 (en) * | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| EP3532072B1 (en) * | 2017-05-17 | 2020-01-01 | TX Medic AB | Treatment of glaucoma |
| JP2020533281A (ja) * | 2017-09-08 | 2020-11-19 | ティーエックス メディック エービー | デキストラン硫酸の新規使用 |
| CN111867647B (zh) * | 2018-03-09 | 2023-01-13 | 卡梅达股份公司 | 用于固定生物物质的方法的改进 |
| SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| JP2000507204A (ja) | 1995-12-18 | 2000-06-13 | ステイヒテイング・サンキン・ブロードボールジーニング | Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化 |
| US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| SE525461C3 (sv) * | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| WO2007028053A2 (en) * | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| WO2007075388A2 (en) * | 2005-12-15 | 2007-07-05 | X-Cell Medical Incorporated | Methods of locally treating and preventing cardiac disorders |
| WO2008134430A1 (en) * | 2007-04-24 | 2008-11-06 | Novelmed Therapeutics Inc. | Methods and compositions of inhibiting complement and cellular activation with dextran sulfate |
| WO2011091167A2 (en) * | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| EP2768522B1 (en) * | 2011-10-18 | 2016-07-27 | CSL Behring GmbH | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| CN102973593A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗肝纤维化药物中的应用 |
| WO2015190989A1 (en) | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
| HRP20190051T1 (hr) * | 2014-06-12 | 2019-03-08 | Tx Medic Ab | Uporaba dekstran sulfata koji ima prosječnu molekularnu masu ispod 10000 da za induciranje angiogeneze kod subjekta |
-
2015
- 2015-07-30 SE SE1551050A patent/SE539575C2/en unknown
-
2016
- 2016-07-15 EP EP16830923.5A patent/EP3328395B1/en active Active
- 2016-07-15 HK HK18106000.5A patent/HK1246640A1/zh unknown
- 2016-07-15 JP JP2018503496A patent/JP6837679B2/ja active Active
- 2016-07-15 DK DK16830923.5T patent/DK3328395T3/da active
- 2016-07-15 US US15/748,519 patent/US10478451B2/en active Active
- 2016-07-15 EA EA201890212A patent/EA034313B1/ru not_active IP Right Cessation
- 2016-07-15 ES ES16830923T patent/ES2882115T3/es active Active
- 2016-07-15 BR BR112018001942A patent/BR112018001942A2/pt not_active Application Discontinuation
- 2016-07-15 CN CN202210555037.5A patent/CN114712385A/zh active Pending
- 2016-07-15 CN CN201680044788.3A patent/CN107921055A/zh active Pending
- 2016-07-15 WO PCT/SE2016/050720 patent/WO2017018922A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN107921055A (zh) | 2018-04-17 |
| WO2017018922A1 (en) | 2017-02-02 |
| EA034313B1 (ru) | 2020-01-28 |
| SE1551050A1 (en) | 2017-01-31 |
| EP3328395A1 (en) | 2018-06-06 |
| EP3328395A4 (en) | 2018-06-20 |
| JP2018521086A (ja) | 2018-08-02 |
| EP3328395B1 (en) | 2021-06-09 |
| CN114712385A (zh) | 2022-07-08 |
| DK3328395T3 (da) | 2021-08-09 |
| US10478451B2 (en) | 2019-11-19 |
| BR112018001942A2 (pt) | 2018-09-18 |
| EA201890212A1 (ru) | 2018-06-29 |
| ES2882115T3 (es) | 2021-12-01 |
| JP6837679B2 (ja) | 2021-03-03 |
| HK1246640A1 (zh) | 2018-09-14 |
| US20180221403A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10478451B2 (en) | Use of dextran sulfate | |
| JP7475395B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| US20230141842A1 (en) | Compounds to Modulate Intestinal Absorption of Nutrients | |
| JP2021152032A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| JP2002540144A (ja) | 心血管及び関連病理学治療のためのピリドキシン化合物の使用 | |
| JP2002518459A (ja) | 修復プロセスを刺激する物質およびその適用方法 | |
| US10925890B2 (en) | Use of dextran sulfate | |
| EP3320901B1 (en) | Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis | |
| WO2015190989A1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
| JP2002526411A (ja) | 網膜病理を治療するためのジルチアゼムの使用 | |
| JP7041961B2 (ja) | ヒト嚢胞性線維症肺上皮における気道表面の生理機能の小分子介在性回復 | |
| CN115427023B (zh) | 用于治疗听力损失的控释配制物及其制备方法 | |
| CN106983738B (zh) | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 | |
| EP3920957A1 (de) | Kardioprotektiver effekt des vasokonstriktion-inhibierenden faktors (vif) | |
| WO2025017193A1 (en) | Methods of treating cardiomyopathy induced by metabolic inflexibility | |
| SE538144C2 (sv) | Use of dextran sulfate for inducing angiogenesis |